Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basic aspects of risk-benefit analysis.

J Beckmann1

  • 1Federal Institute for Drugs and Medical Devices, Berlin, Germany.

Seminars in Thrombosis and Hemostasis
|May 18, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Patellofemoral joint replacement: onlay or inlay?]

Orthopadie (Heidelberg, Germany)·2025
Same author

The impact of stigmatization of psoriasis, atopic dermatitis and mastocytosis in different areas of life-A qualitative interview study.

Skin health and disease·2022
Same author

Status and future of modern technologies in arthroplasty : Results of a survey of the German Society for Orthopedics and Trauma Surgery (DGOU).

Orthopadie (Heidelberg, Germany)·2022
Same author

[Sense and nonsense of patient apps in arthroplasty].

Orthopadie (Heidelberg, Germany)·2022
Same author

Addictions in patients with atopic dermatitis: a cross-sectional pilot study in Germany.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

[Recommendations for unicondylar knee replacement in the course of time : A current inventory].

Der Orthopade·2020
Same journal

Bridging the Gap in Laboratory Monitoring of Extended Half-Life Factor VIII and IX: Can Thrombin Generation Assays Overcome Assay Discrepancies?

Seminars in thrombosis and hemostasis·2026
Same journal

External Quality Assessment for Low Molecular Weight Heparin Monitoring in the Australasia/Asia-Pacific Region.

Seminars in thrombosis and hemostasis·2026
Same journal

Human evolution: between hemorrhage and thrombosis.

Seminars in thrombosis and hemostasis·2026
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
See all related articles

Evaluating medicinal products involves assessing therapeutic efficacy and responder rates for each indication. This study proposes a method to quantify evidence-weighted benefit and risk, crucial for determining favorable benefit-risk relationships.

Area of Science:

  • Pharmacology and Drug Safety
  • Biostatistics and Evidence Synthesis

Background:

  • Medicinal product benefit is indication-specific, derived from therapeutic efficacy and responder rates.
  • Current assessments often lack a structured approach to integrate evidence reliability.

Purpose of the Study:

  • To propose a quantitative framework for evaluating the evidence-weighted benefit and risk of medicinal products.
  • To establish a method for comparing the overall benefit-risk profile across different indications and drugs.

Main Methods:

  • Representing drug benefit as a rectangle (efficacy x responder rate) and risk as a rectangle (seriousness x frequency).
  • Incorporating a 'hierarchy of evidence' to weight these benefit and risk rectangles into evidence-weighted cuboids.
  • Calculating the overall benefit-risk margin by comparing the evidence-weighted benefit cuboid against the sum of evidence-weighted risk cuboids.

Related Experiment Videos

Main Results:

  • The proposed model generates an evidence-weighted benefit cuboid and evidence-weighted risk cuboids for each indication.
  • The benefit-risk relationship is determined by the margin between the benefit cuboid and the total risk cuboids.

Conclusions:

  • This geometric, evidence-weighted approach provides a robust method for assessing and comparing medicinal product benefit-risk profiles.
  • The framework allows for a more nuanced understanding of drug value by integrating efficacy, safety, and evidence quality.